Beijing Balance Medical Technology Co Ltd

Balance Medical announced that as of July 31, 2026, the company had repurchased 340,000 shares, accounting for 0.2480% of total share capital, with a total repurchase amount of 27.29 million yuan and a repurchase price range of 75.6 yuan to 85.45 yuan per share. In the first quarter of 2026, the company achieved revenue of 144 million yuan and net profit attributable to the parent of 41.38 million yuan.

The cross-linked collagen implant, also known as collagen fiber filler II, developed by Beijing Aiborui Biotechnology, a controlled subsidiary of Balance Medical, has received registration approval from the National Medical Products Administration. This product is the first cross-linked collagen implant in China, indicated for injection into the mid to deep dermis of the nasolabial fold area to correct moderate to severe nasolabial fold wrinkles. Clinical trials showed that the wrinkle correction efficacy after injection was significantly better than the control group, with no adverse events related to immunogenicity. This is the second approved product in Aiborui’s collagen series, following collagen fiber filler I.

Lianxun Instruments expects its net profit for the first half of 2026 to grow by 802% to 926% year-on-year, reaching 510 million to 580 million yuan, mainly driven by the development of artificial intelligence technology and rising global computing power demand, which has boosted demand for high-speed optical communication products. Biwin Storage chairman Sun Chengsi has proposed a share buyback of 200 million to 250 million yuan, with all repurchased shares to be cancelled to reduce registered capital. Sino Wealth Electronic estimates first-half net profit will rise 90.82% year-on-year to 165 million yuan, as the global AI and computing power boom spurs MCU demand. OPM Biosciences expects first-half net profit to increase 229% to around 124 million yuan, mainly due to the completion of its acquisition of Pengli Biotech. Ronbay Technology achieved a net profit of 109 million yuan in the first half, swinging from a loss a year earlier, with its lithium iron manganese phosphate products running at full production and sales. In other news, a subsidiary of Balance Medical received approval for China's first cross-linked collagen implant, ArcSoft's actual controller proposed an interim dividend of no less than 60% of first-half net profit, and Chaozhuo Aviation Technology's controlling shareholder is set to change to Taiyang Technology.